Aytu Biopharma

Bull case

• Aytu BioPharma is positioned favorably because its Q4 2025 commercial launch of EXXUA has been described as highly encouraging, while the drug addresses a massive $22 billion U.S. prescription MDD market with 21 million Americans affected and more than 340 million antidepressant prescriptions written in 2024.
• The fundamental appeal is strengthened by EXXUA’s clinical profile: in trials involving more than 5,000 patients, it relieved depressive symptoms and showed sexual side effects and weight gain comparable to placebo, avoiding key warnings that often limit adoption of existing antidepressants.
• Financially, the outlook is conservative yet improving, with FY27 revenue estimates of $68 million to $70 million and a path to profitability by FY28, supporting the view that the stock trades well below future sales potential with limited downside and meaningful upside if EXXUA scales successfully.

Bear case

Aytu BioPharma is facing a fundamentally कमजोर setup, with fiscal Q3 FY26 revenue of $12.4 million declining 33% year over year and pro forma EPS of $(0.43), underscoring weak operating momentum and continued losses. The lack of Q3 guidance adds uncertainty around execution, while the business remains exposed to balance sheet and liquidity risk, commercialization challenges, reimbursement pressure, and competitive threats in a difficult biotech environment. Even though major depressive disorder represents a large U.S. market opportunity with 21.0 million adults affected in 2021, the company’s ability to convert that demand into durable growth appears limited given its dependence on the ADHD Portfolio and ongoing regulatory, clinical, and macroeconomic risks.